[Breast cancer and Her-2].
Division of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research.
Kiyohiko
K
Hatake
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D001932:Brain Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000209:etiology*; D002986:Clinical Trials as Topic; D015195:Drug Design; D004359:Drug Therapy, Combination; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000276:immunology; D005260:Female; D018390:Gene Targeting; D006801:Humans; D000077341:Lapatinib; D011480:Protease Inhibitors / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001897:Boronic Acids; D000069286:Bortezomib; D066246:ErbB Receptors; D000077341:Lapatinib; D011480:Protease Inhibitors; D011719:Pyrazines; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C512478:EGFR protein, human; C485206:pertuzumab